Payment overview · 2025
General Payments
$1,435.02
37 reported records · 8 companies
Healthcare provider profile · identity verified
Kenneth Vera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1417454182
Verified facts
What the public records show
CMS Open Payments records show Kenneth Vera, MD received $1,435.02 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $481.58 | 33.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $433.55 | 30.2% | 14 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $183.67 | 12.8% | 4 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $150.00 | 10.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $109.62 | 7.6% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $34.15 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.44 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.01 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,435.02 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $309.16 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $191.55 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $183.67 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $148.20 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $141.83 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.37 | 9 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 95 |
| Losartan Potassium | Losartan Potassium | 137 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 37 |
| Gabapentin | Gabapentin | 123 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 115 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 37 |
| Omeprazole | Omeprazole | 94 | 34 |
| Metformin Hcl Er | Metformin Hcl | 89 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 22 |
| Famotidine | Famotidine | 81 | 25 |
| Trazodone Hcl | Trazodone Hcl | 77 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 20 |
| Meloxicam | Meloxicam | 70 | 25 |
| Eliquis | Apixaban | 69 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 23 |
| Metformin Hcl | Metformin Hcl | 64 | 27 |
| Lisinopril | Lisinopril | 59 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 13 |
| Ozempic | Semaglutide | 45 | 12 |
| Jardiance | Empagliflozin | 44 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 16 |
| Ammonium Lactate | Ammonium Lactate | 39 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Montelukast Sodium | Montelukast Sodium | 37 | 16 |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 11 |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Pregabalin | Pregabalin | 27 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 14 |
| Ciclopirox | Ciclopirox | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Furosemide | Furosemide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 12 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,435.02 · 37 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, BREZTRI, Biktarvy, FARXIGA, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error